SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2022

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 15 - SUBSEQUENT EVENTS

a. During January and February 2023, the Company sold 3,590,813 ATM Shares under the Sales Agreement. The Company generated gross proceeds equal to approximately $5.5 million in connection with such sales.

b. On January 12, 2023, the Company collected approximately $1.1 million from expense reimbursements in connection with its collaboration with Chiesi. On January 15, 2023, the Company collected approximately $1.1 million from sales to Pfizer. On February 7, 2023, the Company collected approximately $2.3 million from sales of alfataliglicerase to Fiocruz.